Advances inbioinformatics and genomic data analysis have enabled the identification ofcancer antigens that are generally overlooked during immune surveillance; theseneoantigens have been shown to possess substantial therapeutic potential
London
Roots Analysis is pleased toannounce the publication of its recent study, titled, “NeoantigenTargeted Therapies,2019-2030.”
Thereport features an extensive study of the current market landscape, offering aninformed opinion on the likely adoption of these therapeutics over the nextdecade. It features an in-depth analysis, highlighting the capabilities ofvarious stakeholders engaged in this domain. In addition to other elements, thestudy includes:
§ A detailed assessment of the current market landscape of developersengaged in the development of neoantigen targeted therapies.
§ Detailed profiles of developers of neoantigen targetedtherapies (shortlisted on the basis of the number of pipeline products).
§ A detailed publication analysis of close to 300peer-reviewed, scientific articles published during the period 2015-2019 (tillFebruary), highlighting the research focus within the industry.
§ An in-depth analysis of the various patents that have beenfiled / granted related to neoantigens.
§ An analysis of the various partnerships pertaining toneoantigen targeting therapies.
§ An analysis of the investments made at various stages ofdevelopment in companies that are focused on developing neoantigen targetedtherapies.
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
- Target Disease Indication
§ Bone and CartilageCancer
§ Colorectal Cancer
§ Head and Neck Cancer
§ Renal Carcinoma
§ HepatocellularCarcinoma
§ Lung Cancer
§ Gynecological Cancer
§ Others
- Type of Treatment
§ Personalized
§ Off-the-shelf
- Type of Immunotherapy
§ Dendritic CellVaccine
§ DNA / RNA-basedVaccine
§ Protein /Peptide-based Vaccine
§ TIL-based Therapy
- Route of Administration
§ Intradermal
§ Intravenous
§ Subcutaneous
§ Others
- Key Geographical Region
§ North America (US)
§ Europe (UK, Germany,France, Italy, and Spain
§ Rest of theWorld
§ Transcripts ofinterviews held with the following senior level representatives of stakeholdercompanies:
PressRelease: Variation 1 (Format 2)
- Gabriel Nistor, Chief Scientific Officer, AIVITA Biomedical
- Ella Sorani, Vice President Research and Development, BioLineRx
- Heinz Lubenau, Chief Operating Officer and Co-Founder, VAXIMM
Key companies covered in the report
§ Bavarian Nordic
§ Genocea Biosciences
§ Gradalis
§ Immunicum
§ ImmunovativeTherapies
§ IovanceBiotherapeutics
§ Medigene
§ Neon Therapeutics
§ Precision Biologics
§ Vaxon Biotech
For more information please click on the following link:
Other RecentOfferings
1. T-Cell Immunotherapies Market (4th Edition), 2019-2030
2. Novel Immuno-Oncology BiomarkerTesting Market,2019-2030
3. Companion Diagnostics Market (2nd Edition), 2019-2030
About Roots Analysis
Roots Analysis is oneof the fastest growing market research companies, sharing fresh and independentperspectives in the bio-pharmaceutical industry. The in-depth research,analysis and insights are driven by an experienced leadership team which hasgained many years of significant experience in this sector. If you’d like helpwith your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots AnalysisPrivate Limited
Gaurav Chaudhary
+1 (415) 800 3415
